regulatory
confidence high
sentiment positive
materiality 0.65
Inhibikase Therapeutics receives FDA Orphan Drug Designation for IKT-001 in PAH
Inhibikase Therapeutics, Inc.
- FDA granted Orphan Drug Designation to IKT-001 (prodrug of imatinib mesylate) for Pulmonary Arterial Hypertension.
- PAH affects approximately 50,000 people in the United States; ODD provides tax credits, fee exemptions, and 7-year exclusivity upon approval.
- CEO Mark Iwicki cited pre-clinical data at ATS showing improved vascular markers and lower GI toxicity vs. imatinib mesylate.
- ODD applies to the active moiety imatinib, not a specific formulation, per FDA's Office of Orphan Products Development.